Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T globulin 25 versus Sanofi Genzyme anti-thymocyte globulin in pediatric HSCT
IRCT20210523051368N1Phase 3Completed
- Sponsor
- Kowsar Biotechnology
- Start
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of antithymocyte globulin rabbit in graft-versus-host disease (GVHD) (2 arms), sponsored by Kowsar Biotechnology. Primary endpoints: Overall survival and Graft-versus-host disease incidence. Started Feb 2022; status: completed.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on IRCT20210523051368N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210523051368N1.